HUE053558T2 - Adenozin A3 receptor ligandum felhasználásra ektopikus zsírfelhalmozódás kezelésében - Google Patents

Adenozin A3 receptor ligandum felhasználásra ektopikus zsírfelhalmozódás kezelésében

Info

Publication number
HUE053558T2
HUE053558T2 HUE16806299A HUE16806299A HUE053558T2 HU E053558 T2 HUE053558 T2 HU E053558T2 HU E16806299 A HUE16806299 A HU E16806299A HU E16806299 A HUE16806299 A HU E16806299A HU E053558 T2 HUE053558 T2 HU E053558T2
Authority
HU
Hungary
Prior art keywords
receptor ligand
adenosine receptor
fat accumulation
ectopic fat
treating ectopic
Prior art date
Application number
HUE16806299A
Other languages
English (en)
Inventor
Pnina Fishman
Shira Cohen
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of HUE053558T2 publication Critical patent/HUE053558T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE16806299A 2015-11-23 2016-11-22 Adenozin A3 receptor ligandum felhasználásra ektopikus zsírfelhalmozódás kezelésében HUE053558T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL242723A IL242723B (en) 2015-11-23 2015-11-23 A3 adenosine receptor ligand for the treatment of ectopic fat accumulation

Publications (1)

Publication Number Publication Date
HUE053558T2 true HUE053558T2 (hu) 2021-07-28

Family

ID=57485841

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16806299A HUE053558T2 (hu) 2015-11-23 2016-11-22 Adenozin A3 receptor ligandum felhasználásra ektopikus zsírfelhalmozódás kezelésében

Country Status (19)

Country Link
US (2) US10780106B2 (hu)
EP (1) EP3380104B1 (hu)
JP (2) JP6980655B2 (hu)
KR (1) KR102103657B1 (hu)
CN (1) CN108367016B (hu)
BR (1) BR112018010391A8 (hu)
CA (1) CA3005961C (hu)
DK (1) DK3380104T3 (hu)
ES (1) ES2848150T3 (hu)
HR (1) HRP20210020T1 (hu)
HU (1) HUE053558T2 (hu)
IL (3) IL242723B (hu)
LT (1) LT3380104T (hu)
MX (1) MX2018006026A (hu)
PL (1) PL3380104T3 (hu)
PT (1) PT3380104T (hu)
RS (1) RS61372B1 (hu)
SI (1) SI3380104T1 (hu)
WO (1) WO2017090036A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL254535A0 (en) * 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) * 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels
IL272078A (en) 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
EP0708781B1 (en) 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists
WO1997027173A2 (en) 1996-01-24 1997-07-31 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
EP1019427A4 (en) 1997-07-29 2000-07-19 Medco Res Inc N? 6 -SUBSTITUES-ADENOSINE-5'-URONAMIDES USEFUL AS MODULATORS OF ADENOSINE RECEPTORS
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CA2434906C (en) * 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
EP1983990B1 (en) 2006-01-26 2011-03-23 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services A3 adenosine receptor allosteric modulators
DK2227234T3 (da) * 2007-10-15 2014-08-11 Can Fite Biopharma Ltd Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf
US20150018299A1 (en) 2012-01-23 2015-01-15 Can-Fite Biopharma Ltd. Treatment of liver conditions

Also Published As

Publication number Publication date
BR112018010391A8 (pt) 2019-02-26
WO2017090036A1 (en) 2017-06-01
LT3380104T (lt) 2021-05-10
PL3380104T3 (pl) 2021-08-02
IL289841B (en) 2022-07-01
PT3380104T (pt) 2021-02-05
ES2848150T3 (es) 2021-08-05
HRP20210020T1 (hr) 2021-03-05
CA3005961C (en) 2024-06-04
IL242723A0 (en) 2016-02-29
US11291681B2 (en) 2022-04-05
KR102103657B1 (ko) 2020-04-23
US10780106B2 (en) 2020-09-22
JP2020090532A (ja) 2020-06-11
IL242723B (en) 2019-12-31
JP6980655B2 (ja) 2021-12-15
IL259396A (en) 2018-07-31
DK3380104T3 (da) 2021-02-08
IL289841A (en) 2022-03-01
MX2018006026A (es) 2019-01-28
CN108367016A (zh) 2018-08-03
US20180264022A1 (en) 2018-09-20
EP3380104B1 (en) 2020-11-11
JP2018534333A (ja) 2018-11-22
BR112018010391A2 (pt) 2018-11-21
KR20180081595A (ko) 2018-07-16
JP6990934B2 (ja) 2022-01-12
CN108367016B (zh) 2021-07-16
IL259396B (en) 2022-02-01
CA3005961A1 (en) 2017-06-01
SI3380104T1 (sl) 2021-05-31
US20200384009A1 (en) 2020-12-10
RS61372B1 (sr) 2021-02-26
EP3380104A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
IL259242A (en) A component for creating a spray for use in an item for creating a spray
GB2559915B (en) Resistive processing unit
PL3666091T3 (pl) Wyrób do zastosowania w urządzeniach do podgrzewania materiału nadającego się do palenia
IL248708A0 (en) A system for creating a spray containing a multipurpose computing device
IL259607B (en) Inositol derivatives for use in pathological crystallization
IL289841A (en) A3 adenosine receptor ligand for use in the treatment of ectopic fat accumulation
GB2559701B (en) Hook apparatus
EP3362116C0 (en) GREASE FILTRATION DEVICE
EP3509463C0 (de) Matte zur lösbaren aufnahme eines objektes
HK1248642A1 (zh) 功能墊賽車
IL260138A (en) Nonwoven unit
SG10201606767SA (en) Direct resistivity determination
PT2957328T (pt) Sistema de tapetes para desporto
ZA201802418B (en) Process for preparing fat continuous emulsions low in fat
GB201614656D0 (en) Improvements in or relating to apparatus for cooking
HK1216474A2 (zh) 寵物廁所用墊
GB2544893B (en) Grooming apparatus
SG11201708809TA (en) Squeegee device for cleaning
GB201502486D0 (en) Finishing system for 3D prints
GB201516634D0 (en) Design method for dosing unit
GB201600365D0 (en) Mat
GB2537596B (en) Weighing Apparatus
GB201514731D0 (en) System for use in steering apparatus
AU360085S (en) Base for combing floor board